The DOI matches its Crossref record.
Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review and meta‐analysis
Abstract
Summary: ‘Double‐hit lymphomas’ ( DHL ), defined by concurrent MYC and BCL 2 (or, alternatively, BCL 6 ) rearrangements, have a very poor outcome compared to standard‐risk, diffuse large B‐cell lymphomas ( DLBCL ). Consequently, dose‐intensive ( DI ) therapies and/or consolidation with high‐dose therapy and transplant have been explored in DHL , although benefit has been debated. This meta‐analysis compared survival outcomes in DHL patients receiving dose‐escalated regimens [ DI : R‐Hyper‐ CVAD (rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone) or R‐ CODOX ‐M/ IVAC (rituximab, cyclophosphamide, doxorubicin, vincristine, methotrexate/ifosfamide, etoposide, high dose cytarabine); or intermediate‐dose: R‐ EPOCH (rituximab, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone)] versus standard‐dose regimens (R‐ CHOP ; rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) in the first‐line setting. Data were synthesized to estimate hazard ratios of dose‐escalated treatments versus R‐ CHOP using a Weibull proportional hazards model within a Bayesian meta‐analysis framework. Eleven studies examining 394 patients were included. Patients were treated with either front‐line R‐ CHOP ( n = 180), R‐ EPOCH ( n = 91), or R‐Hyper‐ CVAD /rituximab, methotrexate, cytarabine (R‐M/C), R‐ CODOX ‐M/R‐ IVAC ( DI ) ( n = 123). Our meta‐analysis revealed that median progression‐free survival ( n = 350) for the R‐ CHOP , R‐ EPOCH and DI groups was 12·1, 22·2, and 18·9 months, respectively. First‐line treatment with R‐ EPOCH significantly reduced the risk of a progression compared with R‐ CHOP (relative risk reduction of 34%; P = 0·032); however, overall survival ( n = 374) was not significantly different across treatment approaches. A subset of patients might benefit from intensive induction with/without transplant. Further investigation into the role of transplant and novel therapy combinations is necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Liu, Y., & Barta, S. K. (2019) · American Journal of Hematology · doi:10.1002/ajh.25460 · Cited by 488
Diffuse large B-cell lymphoma: R-CHOP failure—what to do?
Coiffier, B., & Sarkozy, C. (2016) · Hematology · doi:10.1182/asheducation-2016.1.366 · Cited by 292
Bachanova, V., Perales, M.-A., & Abramson, J. S. (2020) · Blood Reviews · doi:10.1016/j.blre.2019.100640 · Cited by 46
Metadata
- Authors
- Howlett, C., Snedecor, S. J., Landsburg, D. J., Svoboda, J., Chong, E. A., Schuster, S. J., Nasta, S. D., Feldman, T., Rago, A., Walsh, K. M., Weber, S., Goy, A., & Mato, A.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2015-04-24
- Volume
- 170
- Issue
- 4
- Pages
- 504-514
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2024972915
- Cited by
- 177
- References
- 0
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review and meta‐analysis. https://app.cochat.ai/papers/10.1111/bjh.13463
- The paper
- Howlett, C., Snedecor, S. J., Landsburg, D. J., Svoboda, J., Chong, E. A., Schuster, S. J., Nasta, S. D., Feldman, T., Rago, A., Walsh, K. M., Weber, S., Goy, A., & Mato, A. (2015). Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review and meta‐analysis. British Journal of Haematology. https://doi.org/10.1111/bjh.13463
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.